- Home
- GNTA vs IVVD Comparison
GNTA vs IVVD Comparison
Compare GNTA & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | IVVD |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 692.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNTA | IVVD |
|---|---|---|
| Price | $1.36 | $2.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 123.8K | ★ 4.9M |
| Earning Date | 03-30-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $50,039,000.00 |
| Revenue This Year | N/A | $103.88 |
| Revenue Next Year | N/A | $171.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 332.71 |
| 52 Week Low | $1.30 | $0.35 |
| 52 Week High | $10.00 | $3.07 |
Technical Indicators
Market Signals| Indicator | GNTA | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 28.85 | 55.26 |
| Support Level | $1.80 | $2.15 |
| Resistance Level | $1.77 | $2.59 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 2.22 | 60.40 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.